Table 2. Top signaling pathways implicated by spatially upregulated genes that overlap between superficial and hypertrophic zones as well as intermediate/deep and resting zones.
Zones | Name | Ratio | P-value | Regulated Genes |
SZ and HZ | Inhibition of Angiogenesisby TSP1 | 4/31 (13%) | 1.58E-04 | CD47,GUCY1A3,CD36,MMP9 |
Hepatic Fibrosis/HepaticStellate Cell Activation | 7/133 (5%) | 1.70E-04 | COL1A2,COL1A1,IGF1,MMP13, IGFBP5,SERPINE1,MMP9 | |
Atherosclerosis Signaling | 6/111 (5%) | 3.55E-04 | COL1A2,COL1A1,CD36,MMP13, MMP9, TNFRSF12A | |
Axonal Guidance Signaling | 11/406 (3%) | 7.41E-04 | RAC2,GNG11,TUBB6,IGF1,ADAMTS1, ARHGEF1,MMP13,PRKCH, PLXND1,ABLIM1,MMP9 | |
ERK/MAPK Signaling | 7/179 (4%) | 9.55E-04 | ETS1,RAC2,DUSP1,DUSP6, PPM1L,HSPB1,ELF1 | |
Natural Killer Cell Signaling | 5/93 (5%) | 1.45E-03 | RAC2,TYROBP,FCER1G,PRKCH, INPP5D | |
LXR/RXR Activation | 5/107 (5%) | 2.29E-03 | CD36,ABCG1,PLTP,MMP9, ABCA1 | |
Guanosine NucleotidesDegradation III | 2/12 (17%) | 4.90E-03 | GDA,PNP | |
Xanthine and Xanthosine Salvage | 1/1 (100%) | 8.91E-03 | PNP | |
Dendritic Cell Maturation | 5/155 (3%) | 9.77E-03 | B2M,COL1A2,COL1A1,TYROBP, FCER1G | |
IDZ and RZ | Glutamate Receptor Signaling | 3/59 (5%) | 8.71E-04 | GLS,SLC1A1,GRIA3 |
Role of Osteoblasts,Osteoclasts and Chondrocytesin Rheumatoid Arthritis | 4/215 (2%) | 6.03E-03 | FRZB,BMP3,SFRP5,SFRP1 | |
Asparagine Degradation I | 1/2 (50%) | 6.92E-03 | ASRGL1 | |
Glutamine Degradation I | 1/2 (50%) | 6.92E-03 | GLS | |
Heparan SulfateBiosynthesis (Late Stages) | 2/43 (5%) | 9.77E-03 | CHST11,EXTL1 | |
Heparan SulfateBiosynthesis | 2/50 (4%) | 1.32E-02 | CHST11,EXTL1 | |
Glycogen Biosynthesis II(from UDP-D-Glucose) | 1/5 (20%) | 1.74E-02 | GYS1 | |
Wnt/β-cateninSignaling | 3/158 (2%) | 1.78E-02 | FRZB,SFRP5,SFRP1 | |
Basal Cell CarcinomaSignaling | 2/66 (3%) | 2.14E-02 | GLI2,BMP3 | |
BMP signaling pathway | 2/74 (3%) | 2.63E-02 | BMP3,GREM1 |
*SZ, superficial zone; IDZ, intermediate/deep zone; RZ, resting zone; HZ, hypertrophic zone.